



Catalyst Pharmaceuticals, Inc.
Investor Relations Department
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: CPRX ¹

Last Trade:	3.36
Trade Time:	3:59 PM ET 11/22/17
Change:	0.09  (2.752%)
Day Range	3.23 - 3.39
52-Week Range	1.01 - 3.39
Volume	1,170,709
Market Cap. (\$M)	286.373
Shares Out (M)	85.230

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, amifampridine phosphate, for the treatment of LEMS has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data. Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and Congenital Myasthenic Syndromes (CMS). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 11/21/17 [Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy \(SMA\)](#)
- 11/08/17 [Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- 11/01/17 [Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017](#)
- 10/31/17 [Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome](#)
- 10/16/17 [Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- 03/15/17 [Annual Report \(10-K\)](#)
- 04/14/17 [Definitive Proxy Statement](#)
- 11/08/17 [Quarterly Report \(10-Q\)](#)
- 08/09/17 [Quarterly Report \(10-Q\)](#)
- 05/10/17 [Quarterly Report \(10-Q\)](#)